Scientists Identify Key Immune “Exhaustion Switch,” Opening New Path for Powerful Cancer Treatments

Scientists Identify Key Immune “Exhaustion Switch,” Opening New Path for Powerful Cancer Treatments

In a major scientific breakthrough that could transform cancer care, researchers at Weill Cornell Medicine have uncovered how tumours weaken the body’s immune defences—and how blocking that process can supercharge treatment. The findings, published in Nature Immunology, reveal a critical pathway that drives T cell exhaustion, a major obstacle in modern cancer immunotherapy.

According to the study, cancer cells exploit a molecular signal to drain T cells of their strength, reducing their ability to attack tumours. By blocking this signal, scientists were able to keep T cells active and dramatically enhance their tumour-fighting capacity.

“Our dream is to revive exhausted T cells so the immune system itself can defeat cancer. This discovery brings that future closer,” said co-senior author Dr. Taha Merghoub, noting that T cell exhaustion limits the long-term success of immunotherapies even in patients who initially respond well.

READ ALSO:

• Turkey Football Betting Scandal: 46 Arrested as Match-Fixing Probe Widens
• Four Teenagers Killed in Banki Explosion as Borno Police Probe Deadly IED Blast
• Osimhen Scores Brace as Galatasaray Edge Samsunspor 3-2 in Turkish Super Lig Thriller

The researchers focused on CD47, a protein known as the immune-evading “don’t eat me” signal used by cancer cells. Unexpectedly, the team discovered that T cells also produce CD47—and its levels surge when T cells become exhausted. Tests in mice revealed that animals lacking CD47 developed slower-growing tumours, showing the protein plays a powerful internal role in immune suppression.

Tumours appear to worsen this phenomenon by releasing thrombospondin-1, a protein that binds to CD47 and further weakens T cells. “Remove CD47 or thrombospondin-1, and T cells stay strong,” Merghoub said.

To counter this mechanism, researchers tested TAX2, a peptide that prevents CD47 and thrombospondin-1 from interacting. Mice treated with TAX2 displayed slower growth of melanoma and colorectal tumours, more active T cells, and stronger immune responses. TAX2 also significantly enhanced the effectiveness of PD1 immunotherapy, one of the most widely used cancer treatments.

Lead author Dr. Chien-Huan Weng described TAX2 as a “proof-of-concept,” adding that further work is underway to create safe and targeted ways to block this newly identified exhaustion pathway in human patients.

Scientists say the approach could form a powerful standalone therapy or boost existing immunotherapies, marking one of the most promising advances yet in the fight against cancer.

Scientists Identify Key Immune “Exhaustion Switch,” Opening New Path for Powerful Cancer Treatments